Loading clinical trials...

Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension | Clinical Trials | Clareo Health

RECRUITINGPHASE4

Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension

Comparative Study Between Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension Undergoing Cardiac Surgery

NCT04484675•Zagazig University

View on ClinicalTrials.gov

Summary

The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery

Detailed Description

Milrinone is widely used in cardiac surgery as an inotrope and pulmonary vasodilator agent But , intravenous milrinone has been associated with systemic hypotension and increased requirement for vasoactive drugs The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients scheduled to undergo mitral valve surgery by cardiopulmonary bypass with estimated mean pulmonary artery pressure =\>55 estimated by using preoperative Doppler echocardiography

Exclusion Criteria

•Patients were excluded if they had surgery without CPB, preoperative hemodynamic instability (deﬁned as acute requirement for vasoactive support or mechanical device),Patients with severe LV dysfunction (LV ejection fraction of less than 30% congenital heart disease, a contraindication to transesophageal echocardiography (TEE), emergency surgery or re-do surgeries severe renal or hepatic disease
•, coagulopathy, and thromboembolic disease treated with anticoagulants

Locations (1)

Zagazig University

Zagazig, Sharqia Province, Egypt

Key Dates

Start Date

May 20, 2023

Primary Completion Date

May 10, 2025

Completion Date

May 10, 2025

Last Updated

April 30, 2025

Enrollment

ESTIMATED participants

Conditions

Pulmonary Hypertension Due to Left Heart Disease

Interventions

Milrinone inhalation

DRUG

Milrinone infusion

DRUG

Contacts

Heba M EL-Asser, MD

CONTACT

01062393152 aseelaswad1@yahoo.com

Amany S abdelazeem, MD

CONTACT

01287220016 dola.salah2009@gmail.com

Telemonitoring to Treat Group 2 Pulmonary Hypertension

NCT04882774

Pulmonary Hypertension Due to Left Heart Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 30, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions